Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 43

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 8
Chunk 43
---
Company has the authority to issue 400,000,000 shares of capital stock, consisting of 300,000,000 shares of Common Stock and 100,000,000
shares of undesignated preferred stock, whose rights and privileges will be defined by the Board of Directors when a series of preferred
stock is designated.

Investment
from Largest Shareholder

On
May 19, 2025, Telomir Pharmaceuticals, Inc. (the “Company”) entered into an agreement to raise $3 million in equity financing
through a direct investment by The Bayshore Trust, an entity affiliated with the Company’s largest shareholder. The transaction
was structured as a straight restricted common stock deal with no warrants. The Company issued 333,334 restricted shares of its common
stock, no par value (the “Common Stock”) at a purchase price of $3.00 per share, representing an 18% premium to the closing
share price of the Common Stock of $2.54 on the date of execution (the “Bayshore Financing”). The Company received the initial
payment of $1 million for the Bayshore Financing on May 20, 2025. In July 2025, an additional $2 million was received, for the issuance
of 666,667 shares.

ATM
Agreement

On
February 14, 2025, the Company filed a shelf registration statement with the SEC to facilitate the issuance of our common stock and entered
into an At The Market Offering Agreement (the “ATM Agreement”) with Rodman & Renshaw LLC under which the Company may
offer and sell shares of its Common Stock, with an aggregate offering amount sold of up to $100,000,000. During the nine months ended
September 30, 2025, the Company sold a total of 2,668,300 shares of its common stock, at a weighted average price of $2.17 for total
proceeds of $5,550,008, net of costs of $230,292.

Restricted
Stock Units

On
May 27, 2025, 400,000 fully vested common shares were granted for services to the Company’s CEO. The restricted shares were valued
at $840,000 based on the stock quoted trading price at the grant date and were expensed immediately as compensation expense.

    10

Warrants

In
connection with various transactions and the IPO summarized below, the Company issued stock warrants. Warrant